Print Page | Sign In | Join Today
News & Press: Company News

MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore

Thursday, August 14, 2014  
Share |
MicroVAX, LLC, a clinical stage biotech company located in Prince William County, began a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy. When fully implemented, the MicroVAX vaccine is designed to both destroy pre-existing cancerous tumors and prevent cancer.

Jake Frank, managing member of MicroVAX said, "MicroVAX is delighted to be partnering with Dr. Toh Han Chong and his world class team of clinical cancer immunologists from the National Cancer Center Singapore, and the Singapore Clinical Research Institute on the initial clinical testing of its cancer vaccine."

Dr. Toh Han Chong, Senior Consultant and Deputy Director at NCCS, added, “Our main objective is to assess the safety and benefit of this unique vaccine, which aims to target a common protein on many of the commonest cancers such as colon cancer, breast cancer and ovarian cancer, and provide a specific extra boost to the immune system against cancer at the same time. We will also assess how potent this vaccine can stimulate a meaningful immune response against the cancers.”

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected